Opsona Therapeutics Ltd.

A new UK infectious diseases company,Poolbeg Pharma plc , is being spun out of the CRO, Open Orphan plc and, with a completed fund-raising, is planning to pursue a capital-light clinical model to dev

Alexion Pharmaceuticals Inc. has been left disappointed by top-line data from the Phase II/III registration trial for its first-in-class terminal complement inhibitor Soliris (eculizumab) in preve

Immatics Biotechnologies GMBH ’s latest financing starkly illustrates the difference between biotech exit opportunities in the U.S. and in Europe, where companies are returning to their venture backe

IN VITRO DIAGNOSTICS BioFire Diagnostics Inc. Athyrium Opportunities Fund ups investment in BioFire Diagnostics from $25mm to $45mm BioFire Diagnostics Inc. (formerly Idaho Technology; DNA ana